Acta Scientific Pharmacology

Editorial Volume 2 Issue 12

Pharmacology: SARS-CoV-2 and its Therapeutics

Subodh Kumar Samrat*

Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, USA

*Corresponding Author: Subodh Kumar Samrat, Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, USA.

Received: August 09, 2021; Published: November 01, 2021

The whole world is facing a massive challenge with the SARS-CoV-2 pandemic. Although several vaccines have been developed, manufacturing them at a large scale and immunizing the vast population over the globe is a huge task. In addition to vaccine production and immunization challenges, the emergence of new viral variants is a new threat. Although it is recently reported that the current vaccine will protect people, with reduced efficacy, from different viral variants, it remains elusive how long these vaccines will protect human beings from the coronavirus and its variants.


  1. M G Santoro and E Carafoli. “Remdesivir: From Ebola to COVID-19”. Biochemical and Biophysical Research Communications 538 (2021): 145-150.
  2. M Nojomi., et al. “Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial”. BMC Infectious Diseases1 (2020): 954.
  3. T N MD. “Antiviral Effects of Tranexamic Acid (TXA) as a Preventative Treatment Following COVID- 19 Exposure”., Clinical Trial Registration NCT04550338 (2021).
  4. C B Keragala and R L Medcalf. “Plasminogen: an enigmatic zymogen”. Blood21 (2021): 2881-2889.
  5. T Li., et al. “A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection”. Nature Communication 1 (2021): 4635.
  6. P Pymm., et al. “Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice”. PNAS19 (2021).
  7. J Xu., et al. “Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants”. Nature 7866 (2021): 278-282.
  8. David R Boulware., et al. “A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid -19”. The New England Journal of Medicine 383 (2020): 517-525.
  9. “Lopinavir/ritonavir: A rapid review of effectiveness in COVID-19”. The Centre for Evidence-Based Medicine (2020).
  10. F Robson., et al. “Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting”. Molecular Cell5 (2020): 710-727.


Citation: Subodh Kumar Samrat. “Pharmacology: SARS-CoV-2 and its Therapeutics".Acta Scientific Pharmacology 2.12 (2021): 01-02.


Copyright: © 2020 Subodh Kumar Samrat. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Acceptance rate36%
Acceptance to publication20-30 days

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is May 30, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US